Adderall XR (mixed salts of a single-entity amphetamine product) by Shire Pharmaceuticals received FDA approval as a once-daily treatment for adolescents aged 13 to 17 with attention deficit hyperactivity disorder in July, according to a company news release.
Adderall XR has been approved for children between 6 and 12 since October 2001 and for adults 18 and older since August 2004. Adderall XR is the most prescribed brand of ADHD medication in the United States, according to the release.
The most common adverse events in adolescent trials of Adderall XR included loss of appetite, insomnia, abdominal pain and weight loss.
No comments:
Post a Comment